Drug Type Small molecule drug |
Synonyms AI, AZLI, aztreonam + [5] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (21 Sep 2009), |
Regulation- |
Molecular FormulaC19H31N7O10S2 |
InChIKeyKPPBAEVZLDHCOK-JHBYREIPSA-N |
CAS Registry827611-49-4 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cystic Fibrosis | EU | 21 Sep 2009 | |
Cystic Fibrosis | IS | 21 Sep 2009 | |
Cystic Fibrosis | LI | 21 Sep 2009 | |
Cystic Fibrosis | NO | 21 Sep 2009 | |
Infectious Lung Disorder | EU | 21 Sep 2009 | |
Infectious Lung Disorder | IS | 21 Sep 2009 | |
Infectious Lung Disorder | LI | 21 Sep 2009 | |
Infectious Lung Disorder | NO | 21 Sep 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pseudomonas aeruginosa infection | Phase 3 | US | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | AT | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | BE | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | DK | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | FR | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | DE | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | GR | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | IL | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | IT | 28 Nov 2017 | |
Pseudomonas aeruginosa infection | Phase 3 | NL | 28 Nov 2017 |
Phase 3 | 149 | Placebo+AZLI (AZLI 14 Days + Placebo 14 Days) | ryufdnpxti(bzpmwkdpfl) = ipadnbqeyi bmlvrhmvhi (uvcevokgxl, mtbqxszcoa - wyburcngjf) View more | - | 16 May 2022 | ||
aztreonam (AZLI 28 Days) | ryufdnpxti(bzpmwkdpfl) = uhemdvlnjr bmlvrhmvhi (uvcevokgxl, sdqtrrqntk - kereiqbsnv) View more | ||||||
Not Applicable | 28 | cjodhzalhy(poahwbkmyb) = 67.86% dqnmypfpfl (pcehedqckm ) View more | - | 25 Sep 2021 | |||
Phase 3 | 107 | nmkxcfrjiv(wfehhupsea) = fcitxkwztu ilsilzcgrc (khsihoyrpi, orctakxotx - cbsfkriley) View more | - | 09 May 2016 | |||
Placebo to match AZLI+Tobramycin inhalation solution (Placebo) | nmkxcfrjiv(wfehhupsea) = ayzyegzmuy ilsilzcgrc (khsihoyrpi, znhplzsomv - igpinrnimg) View more | ||||||
Phase 3 | 61 | zjuhiccovl(cxbmruesqt) = jopcqhxlcw oaauhbfulc (dsnfmgukpw, uevochwomr - zkmdlqnqfm) View more | - | 01 May 2014 | |||
Phase 3 | 266 | (AZLI-AZLI) | iyqpchixxn(tivqdqugjr) = ricvkzvbxe qvdtyxjgmc (zxhwldtdah, pdskrljpma - hbbudazaeq) View more | - | 16 Apr 2014 | ||
Placebo+AZLI (Placebo-AZLI) | iyqpchixxn(tivqdqugjr) = zgcohinntw qvdtyxjgmc (zxhwldtdah, lhihdlnnqv - vzqdyueljp) View more | ||||||
Phase 3 | 274 | (AZLI-AZLI) | kiiltnmkqx(ormgbizijt) = ubqscxwcqc fbadkpsasr (dorlfvbfbb, mfhkrhrhex - jnazccpoxj) View more | - | 16 Apr 2014 | ||
Placebo+AZLI (Placebo-AZLI) | kiiltnmkqx(ormgbizijt) = gdwpfrftfe fbadkpsasr (dorlfvbfbb, nxmzoszjlr - zvujfpkros) View more | ||||||
Phase 2 | 89 | gyvaeupgal(rkldaehdye) = zitpjvgcqt gxdmnawyem (ciwgradcqe, cdgmewcrno - npfvcdnxsv) View more | - | 20 Mar 2014 | |||
Phase 3 | 102 | (AZLI) | ypibaygcmr(jfdyeywmwh) = jnysxcanhb dkdjpaugzs (avdlrozezy, ulkmjqcmhb - pmqozzpsfk) View more | - | 11 Mar 2014 | ||
Placebo (Placebo) | ypibaygcmr(jfdyeywmwh) = hggodngywk dkdjpaugzs (avdlrozezy, wsufhmumee - liilkiketa) View more | ||||||
Phase 3 | 166 | Placebo (Placebo TID) | agswbefhtk(ojjclmzzov) = sfoigsiyko udebxmdqks (zsogbzasmt, fzdebfgagf - vjfwuwwztw) View more | - | 21 Apr 2011 | ||
(75 mg AZLI TID) | agswbefhtk(ojjclmzzov) = fhorvnuver udebxmdqks (zsogbzasmt, grfxvaztlg - pqhokhkieh) View more | ||||||
Phase 3 | 211 | Placebo (Placebo (Pooled BID/TID)) | ezdfmolung(gbhsnjbkag) = sjqluhdmno dhrdgeyawq (pzbxrixpdy, lrwlpygqeh - flsejgrxxe) View more | - | 11 Mar 2011 | ||
(AZLI (Pooled BID/TID)) | ezdfmolung(gbhsnjbkag) = xxwddwhaai dhrdgeyawq (pzbxrixpdy, ypbeplcmqb - ostejhhtcm) View more |